A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced phase of pre-clinical investigation or in clinical trials. In addition, a more recent body of evidence indicates that microRNAs (miRNAs) might target effectors of the epigenetic machinery, which are aberrantly expressed or active in cancers, thus reverting those epigenetic abnormalities driving tumor initiation and progression. This review will focus on the broad epigenetic activity triggered by members of the miR-29 family, which underlines the potential of miR-29s as candidate epi-therapeutics for the treatment of hematologic malignancies.

Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, et al. (2015). miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. ONCOTARGET.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

Raimondi L;Botta C;
2015

Abstract

A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced phase of pre-clinical investigation or in clinical trials. In addition, a more recent body of evidence indicates that microRNAs (miRNAs) might target effectors of the epigenetic machinery, which are aberrantly expressed or active in cancers, thus reverting those epigenetic abnormalities driving tumor initiation and progression. This review will focus on the broad epigenetic activity triggered by members of the miR-29 family, which underlines the potential of miR-29s as candidate epi-therapeutics for the treatment of hematologic malignancies.
Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, et al. (2015). miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. ONCOTARGET.
File in questo prodotto:
File Dimensione Formato  
miR-29s a family of epi-miRNAs with therapeutic implications in hematologic malignancies.pdf

non disponibili

Tipologia: Versione Editoriale
Dimensione 945.27 kB
Formato Adobe PDF
945.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/513359
Citazioni
  • ???jsp.display-item.citation.pmc??? 62
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 89
social impact